Intermediate for Ibrutinib. Ibrutinib (trade name: Imbruvica) is a small Bruton's tyrosine kinase (BTK) inhibitor. Ibrutinib is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma. Ibrutinib has been approved by the U.S Food and Drug Administration on November 19, 2013.


Product Name:                  5-Amino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile

Synonyms:                         N/A

CAS Number:                     330792-70-6

Molecular Weight:            276.297

Molecular Formula:          C16H12N4O

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               N#Cc1c(N)[nH]nc1c1ccc(cc1)Oc1ccccc1

  • $138.00
  • Ex Tax: $138.00

Available Options